Abbisko Cayman Limited (HKG:2256)
Hong Kong · Delayed Price · Currency is HKD 12.45
+0.54 (4.53%)
At close: Mar 27, 2026
Abbisko Cayman Revenue
In the year 2025, Abbisko Cayman had annual revenue of 612.12M CNY with 21.45% growth.
Revenue
612.12M CNY
Revenue Growth
+21.45%
P/S Ratio
12.29
Revenue / Employee
2.71M CNY
Employees
226
Market Cap
8.37B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 612.12M | 108.13M | 21.45% |
| Dec 31, 2024 | 503.99M | 484.93M | 2,544.24% |
| Dec 31, 2023 | 19.06M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 22.68M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.41B |
| Shanghai Haohai Biological Technology | 2.75B |
| Lepu Biopharma | 1.04B |
| Everest Medicines | 932.82M |
| HBM Holdings | 908.35M |
| Alphamab Oncology | 861.24M |
| Ocumension Therapeutics | 595.79M |
| CStone Pharmaceuticals | 221.89M |